Back to overview
Michiel van der Heijden group
Michiel van der Heijden
Michiel van der Heijden graduated from medical school at the
Erasmus University in Rotterdam, The Netherlands in 2002. His
research experience has been focused on molecular biology and
included an internship of one year (1999) at the department of
Neurosurgery, University of Maryland(Baltimore, USA) and a 2-year
(2002-2004) fellowship in the lab of Scott Kern, Sydney Kimmel
Cancer Center Johns Hopkins University (Baltimore-USA).
He successfully defended his thesis "The Fanconi anemia/BRCA2
pathway in pancreatic cancer" on September 15, 2005. He then
started his residency in internal medicine/medical oncology. This
residency was interrupted from 2009-2011 when he joined the lab of
Rene Bernards as a postdoc, working on molecular resistance to
targeted therapy in breast and colon cancer. He was one of the
applicants on a 4-year project grant from the Dutch cancer
foundation (KWF): "Identification of genetic modifiers of
sensitivity to mTOR pathway inhibition in breast cancer".
April 1, 2013, he graduated as a medical oncologist and started
a combined clinical/research position at the Netherlands Cancer
Institute / Antoni van Leeuwenhoek hospital, specializing in
urological cancers with a main focus on bladder cancer.